Differentiation and treatment of anemia in HIV disease by Phillips, Kenneth D. & Groer, M
University of Tennessee, Knoxville 
TRACE: Tennessee Research and Creative 
Exchange 
Faculty Publications and Other Works -- Nursing Nursing 
January 2002 
Differentiation and treatment of anemia in HIV disease 
Kenneth D. Phillips 
University of South Carolina, kphill22@utk.edu 
M Groer 
Follow this and additional works at: https://trace.tennessee.edu/utk_nurspubs 
 Part of the Critical Care Nursing Commons 
Recommended Citation 
Phillips, K. D., & Groër, M. (2002). Differentiation and treatment of anemia in HIV disease. Journal of the 
Association of Nurses in AIDS Care, 13(3), 47-72. 
This Article is brought to you for free and open access by the Nursing at TRACE: Tennessee Research and Creative 
Exchange. It has been accepted for inclusion in Faculty Publications and Other Works -- Nursing by an authorized 
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact 
trace@utk.edu. 




of Anemia in HIV Disease
Goal: The goal of this continuing education offer-
ing is to update nurses on HIV-related anemia and be
able to properly diagnose and treat HIV-infected indi-
viduals suffering from anemia in order to improve
quality of life.
Objectives: Upon completion of this offering, the
reader will be able to
1. Define the most common type of anemia in HIV
disease;
2. List the three major categories of anemia;
3. Understand the pathophysiology of anemia and
laboratory tests; and
4. Properly diagnose and treat HIV-related anemia.
How to Earn Continuing Education Credit:
1. Read the article titled “ Differentiation and Treat-
ment of Anemia in HIV Disease.”
2. Complete the test.
3. Send the answer form with your $10 processing
fee (ANAC members) or $15 (non-ANAC members)
check or money order payable to Association of
Nurses in AIDS Care (ANAC) or with credit card
information (MasterCard or Visa ONLY) to ANAC, 80
S. Summit Street, 500 Courtyard Square, Akron, OH
44308, or fax form and credit card information to (330)
762-5813.
4. Answer forms must be postmarked by June 30,
2003. Certificates indicating successful completion of
this offering will bear the date your answer form is
received at ANAC in Ohio.
5. Answer forms may be photocopied.
6. To earn 1.5 contact hours of continuing education
credit, you must achieve a score of 75% (12 of 15 cor-
rect). If you do not pass the test, you may take it again
at no additional charge.
7. The test results will be sent to you within 4 weeks
of our receipt of your answer form. If you have any
questions about the continuing education, please call
(800) 260-6780.
8. The Association of Nurses in AIDS Care is
accredited as a provider of continuing education in
nursing through the Virginia Nurses Association,
which is accredited as an approver of continuing edu-
cation in nursing by the American Nurses Creden-
tialing Center’s Commission on Accreditation.
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Differentiation and Treatment
of Anemia in HIV Disease
Kenneth D. Phillips, PhD, RN
Maureen Groer, PhD, RN, FAAN
Anemia is a frequent complication of HIV disease
that contributes to decreased quality of life and
increased morbidity and mortality. The three major
categories of anemia in HIV disease are anemia due to
impaired red blood cell production, anemia due to
increased red blood cell destruction, and anemia due
to increased red blood cell loss. Although anemia of
chronic illness is the most common type of anemia in
HIV disease, other classifications of anemia may be
encountered. Understanding the pathophysiology of
anemia and laboratory tests that are frequently used to
establish the differential diagnosis of anemia helps to
ensure that HIV-infected individuals will receive
appropriate treatment.
Key words: anemia, HIV/AIDS, nutritional anemia,
hemolytic anemia, blood loss anemia
Hematologic abnormalities are among the most
common pathophysiological processes in HIV/AIDS.
Of these, anemia is thought to be the most common
hematologic abnormality (Coyle, 1997). Anemia
refers to a reduction in the number of circulating red
blood cells, insufficient amount of hemoglobin, or a
decreased hematocrit. Anemia, uncommon in early
HIV disease, is increasingly more prevalent as HIV
disease progresses (Arevalo et al., 1997; Doweiko,
1993; Spivak, Barnes, Fuchs, & Quinn, 1989; Zon,
Arkin, & Groopman, 1987).
Anemia is a serious complication of HIV/AIDS that
is associated with increased morbidity, faster progres-
sion to AIDS, decreased survival time, and increased
mortality (Moore, Keruly, & Chaisson, 1998; Spivak
et al., 1989; Sullivan et al., 1998). HIV-infected indi-
viduals who are severely anemic experience debilitat-
ing symptoms, functional impairment, decreased
sense of well-being, and a poorer quality of life (Cella,
Mo, & Peterman, 1996). For these reasons, it is imper-
ative that nurses in AIDS care be well prepared to man-
age HIV-related anemia. Pathophysiology provides
the scientific basis for understanding HIV-related ane-
mia. Pathophysiology, the study of the pathogenesis,
etiology, clinical manifestations, diagnosis, complica-
tions, and treatment of specific diseases, provides a
scientific basis for the management of HIV-related
anemia. The purpose of this article is to provide
advanced-practice nurses with a knowledge base for
the differential diagnosis and treatment of the most
common types of anemia experienced by HIV-
infected individuals.
JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, Vol. 13, No. 3, May/June 2002, 47-72
Copyright © 2002 Association of Nurses in AIDS Care
Kenneth D. Phillips, PhD, RN, is an associate professor in
the College of Nursing at the University of South Carolina.
Maureen Groer, PhD, RN, FAAN, is a professor and associ-
ate dean for research in the College of Nursing at the Uni-
versity of Tennessee.
Prevalence, Morbidity, and Mortality
of HIV-Related Anemia
As many as 66% to 85% of persons who have pro-
gressed to AIDS have some degree of anemia (Ganser,
1988; Hambleton, 1996; Scadden, Zon, & Groopman,
1989). Zon and Groopman (1988) reported that 8% of
HIV-infected individuals who were asymptomatic,
20% who were symptomatic, and 71% who had pro-
gressed to AIDS were anemic. Spivak et al. (1989)
reported that anemia occurred in 18% of HIV-infected
individuals who were asymptomatic, 50% who were
symptomatic, and 75% who had progressed to AIDS.
Despite advances in the treatment of HIV infection,
the prevalence of anemia in HIV disease has remained
relatively constant (Mocroft et al., 1999; Sullivan et al.,
1998).
Anemia is more common among HIV-infected
women than HIV-infected men (Means, 1997). This
may be due in part to the fact that, in general, anemia is
more prevalent in women than men. Menses, preg-
nancy, and lactation are times when women are more
at risk for anemia. Men are capable of storing greater
amounts of iron, approximately 1000 mg of iron,
whereas women are able to store only 300 to 500 mg
(Leclair, 1997).
Anemia is an independent predictive marker for dis-
ease progression and death in HIV-infected patients
(Mocroft et al., 1999; Rabeneck, Hartigan, Huang,
Soucheck, & Wray, 1997; Spino, Kahn, Dolin, &
Phair, 1997). Controlling for CD4 cell count and viral
load, Mocroft et al. (1999) found that the latest hemo-
globin value was a strong independent prognostic
marker for death. Likewise, successful treatment of
anemia is associated with a reduction in the risk of
HIV-related death (Moore et al., 1998).
Overview of
Normal Erythropoiesis
Hematopoiesis refers to the production and devel-
opment of erythrocytes (red blood cells), leukocytes
(white blood cells), and thrombocytes (platelets). The
tissues of the hematopoietic system consist of the bone
marrow, liver, spleen, lymph nodes, and thymus gland.
These tissues are responsible for the production,
maturation, and destruction of blood cells. In infancy
and early childhood, hematopoiesis occurs in all
bones; however, in adults, it occurs primarily in the red
bone marrow of the pelvic bones, vertebrae, skull, ribs,
sternum, and the proximal ends of the femur. During
periods of severe anemia, the fatty bone marrow, liver,
and spleen can participate in hematopoiesis in a pro-
cess known as extramedullary hematopoiesis
(Gallicchio, 1992).
All blood cells (erythrocytes, leukocytes, and plate-
lets) are derived from progenitor cells called
pluripotent stem cells located in the red bone marrow.
Although relatively few in number (less than 0.01% of
the nucleated cells are in the bone marrow), they pro-
duce all the blood cells an individual will ever have
across the life span. The pluripotent stem cells express
the CD34 surface protein marker and are negative for
CD38. Upon stimulation by growth factors, colony-
stimulating factors, and interleukins, the pluripotential
stem cells give rise to myeloid stem cells that differen-
tiate into erythrocytes, leukocytes, or platelets or lym-
phoid stem cells that become T- or B-lymphocytes
(Bell & Hughes, 1997; Sacher & McPherson, 2000)
(see Figure 1).
Erythropoiesis refers to the production and devel-
opment of erythrocytes. There are at least four
cytokines (hormone-like growth factors) that stimu-
late proliferation, differentiation, and activation of
erythrocytes. These cytokines are erythropoietin,
interleukin-3, granulocyte-monocyte colony-stimu-
lating factor, and monocyte-macrophage colony-stim-
ulating factor (Bell & Hughes, 1997; Sacher &
McPherson, 2000) (see Figure 1).
The primary cytokine responsible for erythro-
poiesis is erythropoietin. Although insignificant
amounts are produced elsewhere in the body, erythro-
poietin is produced in greatest quantities by cells in the
kidneys. The primary stimulus for the synthesis and
release of erythropoietin is hypoxia (decreased oxy-
gen in the tissues). Hypoxia may result from declining
numbers of red blood cells, low hemoglobin levels,
chronic obstructive disease, or inspiring air that con-
tains less than 21% oxygen. Hypoxia stimulates the
production and release of erythropoietin into the circu-
lation. Erythropoietin travels in the circulation to its
target tissue, the bone marrow, where it stimulates
the differentiation of pluripotent stem cells into
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erythrocytes (Bell & Hughes, 1997; Sacher &
McPherson, 2000) (see Figure 1).
Erythrocytes are biconcave disks approximately 7
to 8 µm in diameter. Their biconcave shape maximizes
the red blood cell’s surface area and ability to carry
oxygen for gas exchange. Unlike most other cells in
the body, mature erythrocytes do not contain cell
organelles; therefore, they are unable to synthesize
proteins, including enzymes. Energy, in the form of
adenosine triphosphate (ATP), is produced by the con-
version of glucose to lactate in the Embden-Meyerhof
metabolic pathway. Each erythrocyte contains approx-
imately 300 molecules of hemoglobin enmeshed
within the cell membrane (Bell & Hughes, 1997;
Sacher & McPherson, 2000).
The life span of the average erythrocyte is approxi-
mately 120 days. As erythrocytes age, their
intracellular enzymes decrease and their metabolism
begins to slow. At about day 120, intracellular
metabolism becomes insufficient to maintain the
integrity of the red blood cell. The red blood cell
plasma membrane becomes osmotically fragile, and
hemolysis begins. Normally, about 1% of circulating
red blood cells die and are removed by the
reticuloendothelial system each day (Sacher &
McPherson, 2000). At this rate of erythrocyte destruc-
tion, healthy adults must produce more than 2,400,000
new erythrocytes per second just to maintain a steady
state. At senescence, the spleen breaks down erythro-
cytes and the reticuloendothelial cells degrade hemo-
globin into heme and globin, which are then recycled.
Hemoglobin, the major constituent of erythro-
cytes, is responsible for carrying oxygen to the tis-
sues. Normal adult hemoglobin has four major con-
stituents: globin, protoporphyrin, iron, and 2,3-
diphosphoglycerate (2,3-DPG). Globin chains are
polypeptide chains that are synthesized by the devel-
oping red blood cells. Protoporphyrin is synthesized





























Figure 1. Stages of Hematopoiesis (GM-CSF = granulocyte-monocyte-macrophage colony-stimulating factor, CFU-B = col-
ony-forming unit-B lymphocyte, CFU-T = colony-forming unit-T lymphocyte, CFU-GM = colony-forming
unit-granulocyte-monocyte, CFU-EO = colony-forming unit-eosinophil, CFU-MEG = colony-forming
unit-megakaryocyte, BFU-E = burst-forming unit-erythroid, CFU-E = colony-forming unit-erythroid, EPO =
erythropoietin)
by the developing red blood cells. Heme is formed
when protoporphyrin combines with ferrous iron.
Chemical bonding of heme with globin results in the
formation of hemoglobin. Hemoglobin carries oxygen
from the lungs to the tissues and carbon dioxide from
the tissues to the lungs. Iron is responsible for the char-
acteristic bright red color of oxygenated blood and
dark red color of deoxygenated blood (Ludvigsen,
1992).
For adequate oxygenation to take place, oxygen
must attach to hemoglobin in the lungs and detach
from hemoglobin when it reaches the tissues, where it
can enter the cells and be used for metabolism. At the
alveolar-capillary membrane, hemoglobin must have a
high affinity for oxygen, and at the capillary mem-
brane of other tissues, hemoglobin must have a low
affinity for oxygen. Three factors influence this pro-
cess: body temperature, serum carbon dioxide concen-
tration, and the level of 2,3-DPG contained by red
blood cells. High body temperatures, high carbon
dioxide levels, and elevated 2,3-DPG decrease hemo-
globin’s affinity for oxygen, making it easier for oxy-
gen to dissociate from hemoglobin when it reaches the
tissues. Anemic patients can increase the concentra-
tion of 2,3-DPG in erythrocytes by the nonoxidative
metabolism of the Embden-Meyerhof pathway
(Harmening, 1997; Ludvigsen, 1992).
In adults, only three types of hemoglobin exist
under physiologic conditions: hemoglobin A1 (HbA1;
two α and two β chains), hemoglobin A2 (HbA2; two α
and two δ chains), and hemoglobin F (HbF; two α and
two γ chains). Adult hemoglobin (HbA1) is the pre-
dominant type of hemoglobin during adulthood
(96%-98%). Although fetal hemoglobin (HbF) is the
predominant type of hemoglobin during fetal life, it
only accounts for about 0.5% to 0.8% of the hemoglo-
bin during adult life. Hemoglobin A2 accounts for
1.5% to 3.0% of the hemoglobin in normal adults
(Harmening, 1997; Ludvigsen, 1992).
Laboratory Tests of Erythrocyte
Structure and Function
To correctly diagnose and treat anemia, knowledge
of several laboratory tests is required. The following is
a brief discussion of the laboratory tests used to estab-
lish a diagnosis of anemia. The normal values and
interpretation of these laboratory tests are presented in
Table 1.
Erythrocytes
Red blood cell count. The red blood cell count is the
total number of red blood cells in a cubic millimeter of
blood measured in millions of cells/mm3. A low red
blood cell count indicates anemia. A higher than nor-
mal red blood cell count indicates an overproduction
of red blood cell, known as polycythemia. Although
polycythemia can be a hemoproliferative disorder
(polycythemia vera), secondary polycythemia (due to
chronic hypoxemia) is the most common type of
polycythemia. The red blood cell count is normally
higher in men than in women. Overhydration can
falsely lower the red blood cell count, whereas dehy-
dration has the opposite effect (Fischbach, 1996;
Sacher & McPherson, 2000).
Hemoglobin. The amount of hemoglobin attached
to red blood cells is measured in milligrams per
deciliter (mg/dL). A low hemoglobin indicates ane-
mia. Hemoglobin is normally higher in men than in
women (Fischbach, 1996; Sacher & McPherson,
2000).
Hematocrit. Hematocrit is the percentage of whole
blood that is made up of red blood cells. Red blood
cells make up 97% of the cells in whole blood. White
blood cells and platelets account for the other 3% of
blood cells. When whole blood is centrifuged, it sepa-
rates into two layers, blood cells and plasma. Blood
cells normally make up slightly less than half of the
volume of whole blood (Fischbach, 1996; Sacher &
McPherson, 2000).
Reticulocyte count. The reticulocyte count is the
number of immature red blood cells that have been
released from the bone marrow into the circulation. It
requires approximately 4 or 5 days for reticulocytes to
become mature red blood cells after being released
into the circulation. The reticulocyte count indicates
how well the bone marrow is functioning and how well
50 JANAC Vol. 13, No. 3, May/June 2002
it is responding to erythropoietin. Therefore, the
reticulocyte count is low in bone marrow failure or
when erythropoiesis is insufficient (Fischbach, 1996;
Sacher & McPherson, 2000).
Erythrocyte Indices
Mean corpuscular volume. The mean corpuscular
volume refers to the relative volume (size) of red blood
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Table 1. Normal Values and Interpretation of Laboratory Tests for Anemia
Test Normal Value Interpretation
Red blood cell count Men: 4.6%-6.2% × 106 Low value indicative of anemia
Women: 4.2%-5.4% × 106
Hemoglobin Men: 14-18 g/dL Low value indicative of anemia
Women: 12-16 g/dL
Hematocrit Men: 40%-54% Low value indicative of anemia
Women: 38%-47%
Mean corpuscular volume 80-98 fL Low value indicative of microcytosis
High value indicative of macrocytosis
Mean corpuscular hemoglobin 26-32 fL Low value indicative of hypochromia
High value indicative of hyperchromia
Mean corpuscular hemoglobin concentration 32-36 fL Low value indicative of hypochromia
High value indicative of hyperchromia
Reticulocyte count 0.5%-2.5% Low value indicative of decreased production of
erythrocytes in the bone marrow.
High value indicates increased production of
erythrocytes in the bone marrow
Red cell distribution width 11.6%-14.6% High value indicates greater variation in the size of
red blood cells (anisocytosis).
Serum iron 50-150 µg/dL Low value indicates iron deficiency.
Serum transferrin saturation 20%-45% Low value indicates iron deficiency.
Serum ferritin 12-300 µg/L Low value indicates iron deficiency.
Total iron-binding capacity 240-360 µg/dL High value indicates iron deficiency.
Free erythrocyte protoporphyrin 15-18 µg/L High value indicates iron deficiency.
Serum vitamin B12 level 200-900 pg/mL Low value indicates vitamin B12 deficiency.
Serum folic acid level 3-20 ng/mL Low value indicates folic acid deficiency.
Red blood cell folic acid level 165-600 ng/mL Low value indicates folic acid deficiency.
Direct Coombs’ test Negative A positive direct Coombs’ test indicates the
presence of an antibody on red blood cells and
is useful for investigating hemolysis.
Indirect Coombs’ test Negative A positive indirect Coombs’ test detects antibodies
in the serum against red blood cells and is useful
for investigating the etiology of acquired hemolytic
anemia.
Shilling’s test 15%-40% of the 0.5-µg dose Low value indicates decreased absorption of
vitamin B12 is abnormal.
5%-40% of the 1.0-µg dose If the administration of intrinsic factor with
vitamin B12 corrects the malabsorption, it
is likely pernicious anemia.
Total bilirubin 0.1-1.0 mg/dL Sum of the direct and indirect bilirubin
Serum bilirubin (direct) 0.1-0.3 mg/dL High value may indicate biliary obstruction.
Serum bilirubin (indirect) 0.2-0.8 mg/dL High value may indicate hemolysis.
High value may indicate that the liver is not able to
conjugate bilirubin.
SOURCE: Fischbach (1996) and Sacher and McPherson (2000).
cells. When the mean corpuscular volume is low, red
blood cells are microcytic (smaller than normal). A
high mean corpuscular volume indicates that the red
blood cells are macrocytic (larger than normal)
(Fischbach, 1996; Sacher & McPherson, 2000).
Mean corpuscular hemoglobin. The mean corpus-
cular hemoglobin is a measure of the average amount
of hemoglobin in red blood cells. If the mean corpus-
cular hemoglobin is low, red blood cells are
hypochromic. Hypochromic red blood cells have a
central area of pallor greater than 3 µm. If the mean
corpuscular hemoglobin is high, red blood cells are
hyperchromic. Hyperchromic cells stain gray-blue in
color and are usually larger than normal red blood cells
(Ciesla, 1997).
Mean corpuscular hemoglobin concentration. The
mean corpuscular hemoglobin concentration refers to
the average concentration of hemoglobin in a single
red blood cell. When the mean corpuscular hemoglo-
bin concentration is high, red blood cells are
hyperchromic. When the mean corpuscular hemoglo-
bin concentration is low, the red blood cells are
hypochromic (Fischbach, 1996; Sacher & McPherson,
2000).
Red blood cell distribution width. The red blood cell
distribution width indicates the degree of variation in
size of the red blood cells. If the red blood cell distribu-
tion width is out of normal range, anisocytosis is pres-
ent (Glassman, 1997). A normal red blood cell distri-
bution width in the presence of macrocytosis
(increased mean corpuscular volume) suggests round
macrocytosis that is seen in conditions such as alcohol
abuse, liver disease, or acute hemolytic anemia. An
increased red blood cell distribution width in the pres-
ence of macrocytosis suggests oval macrocytosis that
is seen in conditions such as aplastic anemia, vitamin
B12 deficiency, or folic acid deficiency (Teferri, 2001).
Iron Metabolism
Serum iron. Serum iron is a measurement of the
amount of iron in the serum. A low serum iron level
may indicate iron deficiency. A high serum iron level
may indicate iron poisoning. Serum iron levels must
be evaluated in context with serum transferrin, serum
transferrin saturation, and serum ferritin (Leclair,
1997).
Serum transferrin. Serum transferrin is a measure-
ment of the amount of transferrin, a globulin in the
blood that is responsible for binding and transferring
iron. Transferrin increases in iron deficiency anemia
and decreases in chronic illness and hypoproteinemia
(Fischbach, 1996; Sacher & McPherson, 2000).
Serum transferrin saturation. Serum transferrin
saturation is a calculation that indicates how much iron
is available for hemoglobin synthesis. It is obtained
using the following formula: serum transferrin satura-
tion = serum iron level × 100% total iron-binding
capacity. Serum transferrin saturation should be at
least 20% to ensure that there is enough iron present to
meet the requirements of hemoglobin synthesis
(Fischbach, 1996; Sacher & McPherson, 2000).
Serum ferritin. Serum ferritin is an iron-phosphate-
protein complex. Iron is stored in the body as ferritin.
Ferritin is made by the intestinal mucosa when iron
combines with a protein known as apoferritin. Ferritin
is stored primarily in the reticuloendothelial cells of
the liver, spleen, and bone marrow. Serum ferritin is
more sensitive than either serum iron or total
iron-binding capacity for diagnosing iron deficiency
or overload (Fischbach, 1996; Sacher & McPherson,
2000).
Total iron-binding capacity. Total iron-binding
capacity is the additional amount of iron that
transferrin can bind. In iron deficiency anemia, there is
more transferrin available to transfer iron in the serum
than there is iron (Fischbach, 1996; Sacher &
McPherson, 2000).
Laboratory Tests Used to
Detect Vitamin Deficiencies
Serum folic acid level. Serum folic acid level is the
amount of folic acid present in the serum. Serum folic
acid levels fluctuate in response to dietary intake of
folic acid. Folic acid deficiency may be due to inade-
quate intake (i.e., diet that lacks fresh vegetables or
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chronic illness), increased usage (i.e., pregnancy and
lactation), and certain drugs (i.e., many anti-neoplastic
agents and anti-malarials). Increased folic acid levels
may be seen in pernicious anemia, in vegetarian diets,
and following blood transfusions (Fischbach, 1996;
Sacher & McPherson, 2000).
Red blood cell folic acid level. Red blood cell folic
acid level is the amount of folic acid present in the red
blood cells. Because red blood cell folic acid levels do
not fluctuate as greatly in response to dietary intake of
folic acid, many believe that red blood cell folic acid
level more accurately reflects tissue stores of folic acid
(Fischbach, 1996; Sacher & McPherson, 2000).
Serum vitamin B12. Serum vitamin B12 is the amount
of cyanocobalamin and hydrocobalamin present in the
serum. A low vitamin B12 level may indicate either per-
nicious anemia or malabsorption of vitamin B12. In the
United States, inadequate dietary intake is rarely the
cause of Vitamin B12 deficiency (Fischbach, 1996;
Sacher & McPherson, 2000).
Serum or urine methylmalonic acid. In equivocal
cases of B12 deficiency, increased amounts of
methylmalonic acid in the serum or urine gives added
evidence that B12 is being poorly absorbed. B12 is nec-
essary for the conversion of methylmalonic acid to
succinic acid; therefore, in B12 deficiency increased
levels of methylmalonic acid accumulate in the serum
or the urine. Vitamin B12 is required for the conversion
of methylmalonic acid to acetyl coenzyme A (Teferri,
2001).
Plasma homocystine. Both vitamin B12 and folate
are necessary for the conversion of homocystine to
methionine. Therefore, homocystine levels will be ele-
vated in vitamin B12 deficiency and folate deficiency
(Taghizadeh, 1997).
Schilling’s test. Schilling’s test is a specific test used
to diagnose vitamin B12 deficiency. The purpose of
Schilling’s test is to measure the body’s ability to
secrete biologically active intrinsic factor and to
absorb vitamin B12. The individual must fast for 12
hours before Schilling’s test and 3 hours after the test.
Schilling’s test requires a cooperative patient who can
successfully maintain a 24-hour urine specimen.
Schilling’s test consists of two stages.
In the first stage, the patient is given 0.5 mg to 2.0 µg
of radioactive vitamin B12. Following the oral dose, the
individual is given an intramuscular injection of 1000
µg unlabeled vitamin B12 to fully saturate the liver and
other sites that bind vitamin B12. A 24-hour urine speci-
men is collected. Normally, more than 7% of the radio-
active vitamin B12 should be excreted in the 24-hour
urine sample. If the test is normal at this point, the test
is concluded (Fischbach, 1996; Ludvigsen, 1992). If
less than 7% of the radioactively labeled vitamin B12 is
excreted, the patient undergoes the second stage of the
test.
If less than 7% of the radioactively labeled vitamin
B12 is excreted, two interpretations are suggested. First,
there may be an absence of intrinsic factor. Second,
there may be malabsorption in the ileum. If the results
are abnormally low, the test is repeated in 3 to 4 days to
differentiate between these two possibilities. This
time, the individual is given intrinsic factor and radio-
actively labeled vitamin B12. If the urinary excretion of
radioactive vitamin B12 rises to normal levels, it suggests
an absence of intrinsic factor (pernicious anemia). If the
urinary secretion fails to rise to normal, malabsorption
is considered the etiology of the vitamin B12 deficiency
(Fischbach, 1996; Ludvigsen, 1992).
Laboratory Tests Used
to Diagnose Hemolysis
Serum bilirubin. Serum bilirubin is a test that is ben-
eficial in the diagnosis of hemolytic anemia. There are
two forms of bilirubin: direct bilirubin (conjugated)
and indirect bilirubin (unconjugated). Indirect bili-
rubin is the unbound fat-soluble form of bilirubin that
results from the break down of hemoglobin. Indirect
bilirubin circulates freely in the blood. When the direct
bilirubin circulates through the liver it is bound to a pro-
tein produced by the liver and becomes water-soluble.
Conjugated bilirubin makes up a large part of bile. The
gastrointestinal tract excretes bile. A normal bilirubin
indicates normal liver function and appropriate
hemolysis of senescent cells. A high indirect bilirubin
in the presence of jaundice suggests hemolytic anemia
or liver disease (i.e., hepatitis) that prevents the conju-
gation of bilirubin. A high direct bilirubin in the
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presence of jaundice suggests obstruction of the com-
mon bile duct or hepatic ducts (Fischbach, 1996;
Sacher & McPherson, 2000).
Coombs’ test. The Coombs’ test helps to differenti-
ate the types of hemolytic anemia. The direct Coombs’
test is a measure of the amount of antibodies attached
to the surface of red blood cells. The indirect Coombs’
test is a measure of the amount of antibodies against
red blood cells present in the serum. A positive direct
Coombs’ test most often indicates antibody-mediated
hemolytic anemia and less commonly may occur after
a transfusion reaction or the administration of drugs. A
negative direct Coombs’ test does not rule out
nonautoimmune hemolytic anemia (Fischbach, 1996;
Sacher & McPherson, 2000).
Pathophysiology of
HIV-Related Anemia
Anemia is defined in men as a hematocrit less than
42% (hemoglobin < 14 g/dL) and in women as a
hematocrit less than 37% (hemoglobin < 12 g/dL)
(Sacher & McPherson, 2000). Many classification
systems for anemia exist. One useful classification
system is based on erythrocyte size as determined by
the mean corpuscular volume. Using this system, there
are three broad classifications of anemia: normocytic
anemia (red blood cells are normal in size), microcytic
anemia (red blood cells are smaller than normal), and
macrocytic anemia (red blood cells are larger than nor-
mal). Etiologies for each type of anemia are presented
in Table 2.
The three major causes of anemia in HIV disease
are decreased red blood cell production, increased red
blood cell destruction, and blood loss (see Table 3).
The clinical spectrum of anemia varies from mild to
very severe. The National Cancer Institute (1977) has
developed a grading scale for the severity of anemia
(see Table 4). The symptoms of anemia depend on the
severity. Because the oxygen-carrying capacity of red
blood cells is reduced, the symptoms of anemia are due
to tissue hypoxia. The cardinal symptoms of anemia
are dizziness, weakness, fatigue, and headache. Other
symptoms of anemia are listed in Table 5.
Anemia Due to Impaired
Red Blood Cell Formation
Anemia of Chronic Illness
The most common type of anemia seen in HIV
infection is the anemia of chronic illness. In the anemia
of chronic illness, erythropoiesis is impaired and
reticulocyte response is suppressed. HIV infection
increases the body’s requirement to produce erythro-
cytes while at the same time decreasing the body’s
ability to produce these cells (Scadden et al., 1989;
Zon & Groopman, 1988).
Pathophysiology
The major cause of anemia in HIV disease is
impaired erythropoiesis (Coyle, 1997; Mitsuyasu,
1999). Intrinsic immune mechanisms, opportunistic
infections, opportunistic malignancies, medications,
and malabsorption of vitamins, trace elements, and
other nutrients may contribute independently or syner-
gistically to impaired erythropoiesis. The anemia of
chronic illness associated with HIV disease is typi-
cally associated with low serum erythropoietin levels
(Spivak et al., 1989).
A rise in the level of the inflammatory cytokines
(interleukin-1, interleukin-6, tumor necrosis factor,
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Table 2. Classification of Anemia Based on Red Blood Cell Size
Decreased Mean Corpuscular Volume Normal Mean Corpuscular Volume Elevated Mean Corpuscular Volume
Iron deficiency anemia Anemia of chronic illness Acute hemolytic anemia
Thalassemia Early iron deficiency anemia Zidovudine or other drug-induced anemia
Anemia of chronic illness Hemolytic anemia Vitamin B12 deficiency anemia
Aplastic anemia Folate deficiency anemia
Drug-induced bone marrow suppression
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Table 3. Three Major Causes of HIV-Related Anemia
Classification Type Etiological Factor




















Iron Deficiency Anemia Inadequate intake of iron
Iron-deficient diet
Inadequate absorption of iron
Achlorhydria
Decreased absorptive area
Excess loss of iron
Menorrhagia
Gastrointestinal bleeding
Increased physiologic demand for iron
Pregnancy
Lactation
Increased growth in infancy and childhood




Consumption by small-bowel bacteria
Consumption by fish tapeworms
Decreased absorptive area in the ileum














and interferon) marks the progression of HIV disease.
Likewise, the degree of anemia worsens as the serum
levels of these inflammatory cytokines rise in
HIV-infected individuals. These cytokines have been
shown to inhibit erythropoiesis in vitro. Tumor necro-
sis factor-α has been shown to inhibit erythropoiesis in
vitro. Interferon-γ has been shown to suppress the for-
mation of the erythroid colony-forming units (Spivak
et al., 1989).
Several opportunistic organisms have been shown
to infi l t ra te the bone marrow and disrupt
erythropoiesis. The most common infectious agents
associated with HIV-related anemia include Mycobac-
terium avium complex, Mycobacterium tuberculosis,
Histoplasma , Cryptococcus , Coccidiodes ,
Pneumocystis carinii, and Leishmania (Hambleton,
1996). In immunosuppressed individuals, M. avium
complex may produce a widely disseminated infection
involving the blood, bone marrow, and other tissues.
M. avium infection has been highly implicated as a
cause of HIV-related anemia. Anemia due to M. avium
is usually isolated to a reduction in red blood cells.
Anemia resulting from other organisms is frequently
associated with pancytopenia (Hambleton, 1996).
Another organism strongly associated with
HIV-related anemia is Parvovirus B19 infection
(Hambleton, 1996).
Several drugs used to combat HIV and its complica-
tions may contribute to the anemia that is seen in HIV
disease (Aboulafia, 1997). Zidovudine is a reverse
transcriptase inhibitor that is most commonly associ-
ated with anemia in HIV disease (Northfelt, 1999).
Zidovudine inhibits the development of erythrocytes,
lymphocytes, and platelets (Walker et al., 1988). In the
early clinical trials, 34% of the patients receiving
zidovudine demonstrated a statistically significant
reduction in hemoglobin after 6 weeks of therapy
(Richman et al., 1987). Now that zidovudine is being
administered at lower doses in combination with other
antiretrovirals, the incidence of severe anemia has
declined (Collier et al., 1990; Eron et al., 1995;
Volberding et al., 1990). Anemia related to zidovudine
therapy often subsides when the drug is withdrawn.
Other reverse transcriptase inhibitors may be less
myelosuppressive than zidovudine and should be con-
sidered for anemic patients.
Zidovudine increases the mean corpuscular volume
of red blood cells. Thus, mean corpuscular volume is
often used as a measure of adherence to zidovudine
therapy. Other drugs that increase the mean corpuscu-
lar volume are trimethoprim/sulfamethoxazole and
dapsone (Northfelt, 1999).
In the anemia of chronic illness, the red blood cells
are usually normochromic (normal mean corpuscular
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Table 3. continued
Classification Type Etiological Factor
Increased destruction of erythrocytes Antibody-mediated hemolytic anemia
Sickle cell anemia A hereditary disorder in which the gene
responsible for coding for hemoglobin
substitutes valine for glutamic acid in the NH2
terminal of the β chain
Hereditary spherocytosis A hereditary disorder caused by an intrinsic
defect in the red blood cell membrane
Glucose-6-phosphate dehydrogenase Hereditary disorder caused by a deficiency of
deficiency glucose-6-phosphate, which is an enzyme that
is key in the Embden-Meyerhof metabolic
pathway; antioxidants, infection, or fever can
precipitate a hemolytic crisis
Increased loss of erythrocytes Acute blood loss Hemophilia
Gastrointestinal bleeding
Menstruation
Chronic blood loss Gastrointestinal bleeding
Menstruation
hemoglobin and mean corpuscular hemoglobin con-
centration) and normocytic (normal mean corpuscular
volume). However, microcytic, hypochromic red
blood cells are sometimes seen in the anemia of
chronic illness. Anisocytosis is frequently observed
(increased red blood cell distribution width). Disrup-
tion of iron metabolism is manifested by low serum
iron, total iron-binding capacity, and transferrin satu-
ration with an elevated serum ferritin level (Linker,
2001).
Low serum erythropoietin levels are associated
with HIV-related anemia. In a cohort study that
included HIV-infected individuals at all stages of the
illness, researchers in Greece identified antibodies to
erythropoietin. Circulating autoantibodies to erythro-
poietin significantly predicted anemia and were signif-
icantly associated with higher erythropoietin levels
(Sipsas et al., 1999).
Treatment
The first step in the treatment of HIV-related ane-
mia is to identify the underlying etiology of the
anemia. Review the medications, especially the
antiretrovirals, currently being taken. All assessment
data, especially cardiovascular, respiratory, and skin
data, should be considered when initiating therapy for
HIV-related anemia. Therapy should be based not
solely on the individual’s hemoglobin level but also on
the physical assessment data. Consider substituting
another drug for one that is myelosuppressive. For
instance, it is often possible to substitute another
nucleoside analog reverse transcriptase inhibitor for
zidovudine.
Opportunistic infections. Constant vigilance in the
treatment of opportunistic infections is required. In
particular, prevention and treatment is required for the
following organisms known to be associated with
HIV-related anemia: M. avium complex, M. tuberculo-
sis, Histoplasma, Cryptococcus, Coccidiodes, P. carinii,
Leishmania, and P. B19.
Recombinant erythropoietin. Erythropoietin alfa, a
recombinant, biosynthetic form of erythropoietin, is
synthesized using recombinant DNA technology.
Recombinant erythropoietin stimulates two progeni-
tors of erythrocytes, the burst-forming units and the
colony-forming units. The safety and efficacy of
recombinant erythropoietin for treating anemia have
been demonstrated (Henry et al., 1992). The initial
dosage of epoietin alfa is 100 to 300 units/kg subcuta-
neously or intravenously three times per week. The
maintenance dose is individually titrated to keep the
hematocrit between 36% and 40%. The response to
erythropoietin alfa depends on the endogenous serum
erythropoietin level prior to treatment. A good
response to erythropoietin is usually observed in indi-
viduals with a serum erythropoietin less than 500
µU/mL (American Hospital Formulary Service,
2001). Little response to erythropoietin therapy is
observed in individuals with a serum erythropoietin
greater than 500 µU/mL (American Hospital Formu-
lary Service, 2001).
Red cell transfusions. Red cell transfusions are used
with caution in HIV disease because blood transfu-
sions have been shown to be immunosuppressive, to
increase HIV replication, to accelerate disease pro-
gression, to decrease the survival time in HIV disease,
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Table 4. National Cancer Institute’s Anemia Grading Scale
Grade Hemoglobin Level (g/dL)
I mild 10.0 to normal
II moderate 8.0 to 9.9
III severe 6.5 to 7.9
IV very severe < 6.5
SOURCE: National Cancer Institute (1977).










and to transmit a number of blood-borne pathogens
(Groopman, 1997). Proteins on the surface of white
blood cells in transfused blood are known to be
immunosuppressive. Following transfusion, HIV-
infected blood recipients have decreased CD4:CD8
ratios (Kaplan, Sarnaik, Gitlin, & Lusher, 1984), natu-
ral killer cell activity (Kaplan et al., 1984), lymphocyte
blastogenesis (Waymack et al., 1986), and cell-mediated
recall of antigens (Tartter, Heimann, & Aufses, 1986;
Schot & Schuurman, 1986). Transfusions induce cel-
lular immune activation, and this activation appears to
increase HIV viral replication (Margolick, Volkman,
Folks, & Fauci, 1987; Mudido et al., 1996).
Iron Deficiency Anemia
Pathophysiology
Worldwide, iron deficiency is the most common
type of anemia. Deficient intake of iron ,
malabsorption of iron, increased requirement of iron,
and blood loss most commonly cause iron deficiency.
Although deficient iron intake is uncommon in adults,
it should be considered as a cause of iron deficiency for
all HIV-infected infants, children, adolescents, and
adults. Malabsorption may result from inflammatory
changes of the gastrointestinal mucosa. Acute and
chronic blood loss can result from conditions such as
Kaposi’s sarcoma, excessive menstruation, or gastro-
intestinal bleeding. Increased demands for iron are
experienced during infancy, adolescence, pregnancy,
and lactation.
In the United States, the average diet provides
approximately 10 to 15 mg of iron per day. Normally, 1
mg of iron is absorbed primarily across the mucosal
cells of the duodenum and upper jejunum. Iron is
transported in the blood by transferrin. In the blood,
iron combines with apoferritin, a protein present in the
blood, and becomes ferritin, the storage form of iron.
Likewise, 1 mg of iron is lost per day through fecal or
urinary excret ion. Women who experience
menorrhagia (excessive menstrual bleeding at the time
of menstruation) may lose as much as 3 to 4 mg of iron
per day (Leclair, 1997; Sacher & McPherson, 2000).
In iron deficiency anemia, pica is frequently experi-
enced, but the patient often fails to report unusual crav-
ings for ice, starch, clay, or other substances. Signs of
severe iron deficiency anemia include glossitis
(inflamed tongue), cheilitis (fissures in the corner of
the mouth), koilonychia (thin concave nails with
raised edges sometimes called spoon nails), blue
sclera, and dysphagia due to the formation of esopha-
geal webs (Leclair, 1997; Sacher & McPherson,
2000).
In early iron deficiency anemia, a decrease in serum
ferritin may be observed. As iron deficiency anemia
progresses, the red blood cells become hypochromic
(decreased mean corpuscular hemoglobin and mean
corpuscular hemoglobin concentration) and
microcytic (decreased mean corpuscular volume). The
red blood cell count may be normal during early iron
deficiency. As iron stores deplete, serum transferrin
usually increases. Typically, the amount of transferrin
saturated with iron (transferrin saturation) decreases
to less than 10% (Teferri, 2001).
Treatment
Iron supplementation can be administered orally or
parenterally. The oral route is preferred because
parenteral iron supplementation is associated with
increased risk of anaphylaxis. Ferrous sulfate is often
the oral iron preparation of choice because this form of
iron is less expensive and more readily absorbed. Fer-
rous gluconate and ferrous fumarate are other common
iron preparations that may be administered orally. Oral
administration of iron may produce constipation, diar-
rhea, dark stools, and/or epigastric pain (American
Hospital Formulary Service, 2001) (see Table 6).
Parenteral iron therapy using iron dextran should
only be used when the patient is unable to tolerate any
oral iron preparation or when malabsorption is the eti-
ology of iron deficiency. Iron dextran can be given
intramuscularly or as an intravenous infusion over 4 to
6 hours. Severe anaphylactic reactions have been
observed following parenteral iron therapy.
Anaphylactic reactions most often occur within min-
utes of onset of administration. Anaphylaxis is charac-
terized by respiratory difficulty (wheezing, broncho-
spasm, rigor, dyspnea, and cyanosis), tachycardia, and
hypotension. Because respiratory and/or cardiac arrest
are possible, parenteral iron therapy should only be
administered by persons who are able to deliver
resuscitative measures, if needed (American Hospital
Formulary Service, 2001).
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The following formula is used to calculate the total
dosage of iron dextran that is required for iron defi-
ciency anemia (the weight is lean body weight rather
than total body weight):
Total dose of iron dextran in mL = [0.0476 × weight ×
(hemoglobinnormal – hemoglobinmeasured)] + 1 mL per 5 kg
of weight (up to a maximum of 14 mL) (American
Hospital Formulary Service, 2001, p. 1364).
The following formula is used to calculate the total
dosage of iron dextran that is required for iron replace-
ment secondary to blood loss:
Total dose of iron dextran in mL = 0.02 × blood loss
in mL × hematocrit (expressed as a decimal fraction)
(American Hospital Formulary Service, 2001, p. 1364).
Reticulocytosis indicates that iron supplementation
is effective. Reticulocytosis should appear within 10
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Table 6. Medications Commonly Used for Treating Anemia
Classification Generic Name Route Usual Therapeutic Dosage Nursing Considerations
Anti-anemia drugs Epoietin alfa Subcutaneously 100-300 units/kg 3 times The target hematocrit range is 36%-40%.
Intravenously weekly Treatment with epoietin alfa is usually
indicated for patients with endogenous
erythropoietin levels ≤500 mU/mL.
Oral iron Ferrous sulfate Orally Large dose for adults: All oral iron preparations should be taken
preparations 50-100 mg of elemental 2 hours before or 1 hour after a meal.
iron orally three times daily
Ferrous gluconate Smaller dose for adults: Vitamin C increases the absorption of iron
60-120 mg of elemental from the gastrointestinal tract.
iron orally daily in two or
three divided doses
Ferrous fumarate Pediatric dose: 3-6 mg/kg of Reticulocytosis usually begins by the 10th
elemental iron daily in two day and indicates effective therapy.
or three divided doses
Parenteral iron Iron dextran Intramuscularly The dosage is calculated using Iron dextran is used for iron deficiency
preparation a formula that takes body when oral iron replacement is unfeasible
weight and desired and or ineffective.
observed hemoglobin levels
into consideration
Intravenously Iron dextran is not recommended for
children under 4 months of age.
The most common adverse reaction of
iron dextran is anaphylaxis.
A test dose should be given prior to
initiating iron dextran therapy.
The test dose for an adult is 25 mg
of iron dextran.
The test dose for a child weighing
10 to 20 kg is 15 mg of iron dextran.
The test dose for a child weighing
<10 kg is 10 mg of iron dextran.
Must be given by the Z-track method if
given intramuscularly
Reticulocytosis usually begins by the
fourth day after administration and
indicates effective therapy.
Vitamins Folic acid Orally Initial dose: 5 mg/day Folic acid is commonly administered to
for 4 months prevent folic acid deficiency.
days following the initiation of therapy. Following the
appearance of reticulocytosis, the hemoglobin is
expected to rise 0.1 to 0.2 g per deciliter if iron defi-
ciency is the etiology of the anemia (Sacher &
McPherson, 2000).
Vitamin B12 Deficiency Anemia
Pathophysiology
Vitamin B12 is required for folate metabolism.
Therefore, vitamin B12 deficiency also leads to defec-
tive DNA synthesis. There are two forms of vitamin
B12, cyanocobalamin and hydroxycobalamin, which
are synthesized by microorganisms ubiquitous in
nature. Humans obtain vitamin B12 from eating meat.
The average American diet provides 5 to 30 µg of vita-
min B12; however, only 1 to 5 µg are absorbed. The
liver stores from 3000 to 5000 µg of vitamin B12,
enough to meet the requirements for about 6 months.
For that reason, dietary deficiency of vitamin B12 is
rarely ever the cause of vitamin B12 deficiency in this
country (Sacher & McPherson, 2000).
Malabsorption due to a lack of intrinsic factor is the
most common cause of vitamin B12 deficiency. Vita-
min B12 deficiency due to a lack of intrinsic factor is
called pernicious anemia. Intrinsic factor, a substance
produced by parietal cells in the stomach, is responsi-
ble for the absorption of vitamin B12 in the terminal
ileum. Intrinsic factor binds to vitamin B12 and to
receptor sites in the lumen of the terminal ileum. This
binding process promotes the absorption of vitamin
B12. Partial or total gastrectomy may lead to decreased
production of intrinsic factor and decreased absorp-
tion of vitamin B12. Inflammatory changes to the ileal
wall secondary to HIV disease may lead to decreased
absorption of B12. Because intestinal bacteria use the
vitamin B12 present in the intestinal lumen, another
cause of vitamin B12 deficiency is bacterial over-
growth. Bacterial overgrowth often follows aggressive
antibiotic therapy and may increase the amount of
vitamin B12 that is used (Sacher & McPherson, 2000).
In addition to the general symptoms of anemia, the
person with vitamin B12 deficiency may present with
gastrointestinal symptoms such as a sore mouth, a
beefy or atrophic tongue (glossitis), or diarrhea. In
addition, neurologic signs due to peripheral
neuropathy (i.e., impaired gait, paresthesia, and
decreased vibratory sense in the extremities) may be
seen. Neurologic signs may also include decreased
ability to think and reason and personality change
(Sacher & McPherson, 2000).
Serum vitamin B12 level. Serum vitamin B12 level is a
simple and relatively inexpensive test to confirm vita-
min B12 deficiency. A low value indicates vitamin B12
deficiency (Sacher & McPherson, 2000).
Treatment
Cyanocobalamin (vitamin B 1 2) . Although
cyanocobalamin may be given orally in large doses, it
is poorly absorbed from the gastrointestinal tract in the
absence of intrinsic factor. Cyanocobalamin may also
be given nasally. The preferred route is subcutane-
ously or intramuscularly. For pernicious anemia, life-




Folic acid is necessary for thymidine synthesis.
Thymidine is an amino acid that is found in DNA but is
absent in RNA. Thus, folate deficiency impairs the
synthesis of DNA in the developing red blood cells.
The most likely cause of folic acid deficiency ane-
mia in the general population is inadequate dietary
intake. Foods that are rich in folate include asparagus,
black-eyed peas, lettuce, spinach, collards, broccoli,
liver, yeast, and mushrooms. Overcooking vegetables
in water decreases the amount of folate they contain. A
number of drugs that are used in the treatment of HIV
disease antagonize the use of folate. These include
trimethoprim, methotrexate, and trimetrexate. A drug
that decreases the absorption of folic acid is the
antitubercular drug cycloserine. Giardial infestation
may impair the absorption of folic acid. Pregnancy
increases the amount of folate that is needed. There is
strong evidence that folic acid deficiency leads to neu-
ral tube deficits in the developing fetus. All women of
reproductive age should begin folate therapy prior to
becoming pregnant (Sacher & McPherson, 2000).
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The signs and symptoms of folic acid deficiency
anemia are the same as for vitamin B12 deficiency ane-
mia. Neurological signs and symptoms may not be
present (Teferri, 2001).
Folate deficiency anemia is manifested by a low
serum folic acid level (< 3 ng/mL) and a low red blood
cell folic acid level (< 165 ng/mL). An effective
response to folic acid therapy is indicated by a prompt
and pronounced increase in the number of circulating
reticulocytes (Sacher & McPherson, 2000).
Treatment
Except for cases in which malabsorption is the basis
for folic acid deficiency, a daily dose of folic acid 1 to 2
mg by mouth is sufficient. In cases where folic acid
deficiency is due to malabsorption, a daily parenteral
dose of 1 to 2 mg folic acid may be administered
(American Hospital Formulary Service, 2001).
Anemia Due to Increased
Red Blood Cell Destruction
Hemolysis refers to the destruction of red blood
cells. Rapid and early destruction of red blood cells
leads to hemolytic anemia. When the red blood cells
are destroyed, they release free hemoglobin into the
circulation. Through a series of steps, hemoglobin is
broken down into bilirubin in the blood. This soluble
form of bilirubin is referred to as unconjugated or indi-
rect bilirubin. Glucuronic acid, a substance found in
liver cells, acts on bilirubin to conjugate it to an insolu-
ble form of bilirubin (direct bilirubin) that can be
excreted as bile through the gastrointestinal system. In
hemolytic anemia, there is more indirect bilirubin in





Frequently, HIV-infected individuals present with
hypergammaglobulinemia (excessive gamma globulin
in the blood). A positive direct Coombs’ test, indicat-
ing the attachment of immunoglobulins to the red
blood cell membrane, is generally seen in non-AIDS-
related antibody-mediated hemolytic anemia.
Although approximately 20% to 40% of HIV-infected
individuals have a positive direct Coombs’ test (Telen,
Roberts, & Bartlett, 1990), the incidence of
AIDS-related antibody-mediated hemolytic anemia is
rare (Coyle, 1997). HIV-infected individuals who
experience antibody-mediated hemolytic anemia
become severely anemic and often require numerous
transfusions (Saif, 2001). Other signs of AIDS-related
antibody-mediated hemolytic anemia include a low
serum haptoglobin, microspherocytes on the periph-
eral blood smear, splenomegaly, increased indirect bil-
irubin, and hyperplasia of the red blood cell precursors
in the bone marrow. A characteristic finding of antibody-
mediated hemolytic anemia is reticulocytosis; how-
ever, reticulocytosis is noticeably absent in AIDS-
related antibody-mediated hemolytic anemia (Coyle,
1997).
Treatment
Treatment of AIDS-related antibody-mediated
hemolytic anemia includes glucocorticoids, intrave-
nous gammaglobulin, and splenectomy (Coyle, 1997).
Hereditary Spherocytosis
Pathophysiology
Normal red blood cell membranes comprise 10
major and 200 minor proteins. Six proteins, spectrin,
ankyrin, adducin, band 4.1, band 3, and band 4.2, form
the cytoskeleton of red blood cells and help maintain
their normal biconcave shape. In hereditary
spherocytosis, one or more of these proteins are defec-
tive. Spectrin is the protein that is most often defective.
This defect decreases the surface area of the red blood
cell membrane and allows the cell to become spherical
in shape, to swell more than normal, and to become
osmotically fragile. Together, these factors decrease
the survival time of the spherocytes (Zail & Coetzer,
1997).
Hereditary spherocytosis is the most prevalent form
of inherited hemolytic anemia in Caucasians (Zail &
Coetzer, 1997). It is usually transmitted by an
autosomal dominant inheritance pattern (75%); how-
ever, it may also be transmitted by an autosomal
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recessive pattern (25%). Due to chronically elevated
serum bilirubin levels, many individuals with hered-
itary spherocytosis often develop pigment gall-
stones. The most common pattern for hereditary
sphero-cytosis is chronic mild hemolytic anemia.
Approximately 10% of individuals with hereditary
spherocytosis may experience a severe hemolytic epi-
sode requiring transfusion. Rarely, aplastic crises
complicate hereditary spherocytosis. The most com-
mon cause of such crises is P. B19 infection (Zail &
Coetzer, 1997).
The patient with hereditary spherocytosis may pres-
ent with jaundice, anemia, and splenomegaly from
birth to adulthood. The hallmark of hereditary
spherocytosis is the presence of spherocytes on the
peripheral blood smear. Red blood cells from indi-
viduals with hereditary spherocytosis have
increased osmotic fragility and undergo more rapid
autohemolysis when allowed to incubate in a test tube
for 48 hours at body temperature. Electrophoresis is
used to determine which structural protein is defective
(Teferri, 2001).
Treatment
Splenectomy is beneficial for most patients. The
life span of red blood cells returns to near normal lev-
els (120 days) following splenectomy. Following
splenectomy, the individual becomes more susceptible
to bacterial infections and may require prophylactic
antibiotics. Life-threatening sepsis may occur follow-




Red blood cells contain no nuclei. Glucose-6-
phosphate dehydrogenase (G6PD) is a protein
required for aerobic glycolysis. In red blood cells,
G6PD catalyzes the conversion of glucose to
glutathione. Glutathione prevents hemoglobin from
becoming denatured. In the presence of glutathione
deficiency, oxidative destruction of the globin chains
of hemoglobin occurs, and the red blood cell mem-
brane becomes damaged. Most individuals with G6PD
deficiency are asymptomatic most of the time and
often reach adulthood before learning that they have
G6PD deficiency. Certain drugs that are used in the
treatment of HIV and other conditions, such as malaria,
are known to induce hemolysis is G6PD-deficient
individuals. Fava beans often trigger hemolysis
(Sacher & McPherson, 2000). These drugs are sum-
marized in Table 6.
G6PD deficiency is one of the most prevalent
genetic disorders known. G6PD deficiency is trans-
mitted by an X-linked recessive pattern of inheritance.
G6PD deficiency is expressed in men who inherit the
gene from their mothers who are carriers. G6PD defi-
ciency is expressed in women only when both X chro-
mosomes contain the gene (homozygous). G6PD defi-
ciency is more common in African Americans, Asians,
and people of Mediterranean descent (Sacher &
McPherson, 2000; Sim, McCarron, & Glassman,
1997).
The individual may become jaundiced, and his or
her urine may become tea colored. Hemoglobin and
hematocrit levels decrease. Heinz bodies (precipitated
hemoglobin) appear on the peripheral blood smear.
Serum bilirubin levels increase and haptoglobin levels
decrease. Addition of certain drugs may result in the
formation of Heinz bodies in an in vitro blood sample.
Other tests that can be used to confirm the diagnosis of
G6PD deficiency are the methemoglobin reduction
test (sensitive), the ascorbate-cyanide test (not spe-
cific), the fluorescent spot test (sensitive and specific),
and the specific G6PD assay (sensitive and specific)
(Sacher & McPherson, 2000; Sim et al., 1997).
Treatment
Prevention remains the best treatment for G6PD
deficiency hemolytic anemia. Avoid oxidant drugs
that may precipitate a hemolytic crisis.
Anemia Due to
Increased Blood Loss
Chronic Blood Loss Anemia
Pathophysiology
Chronic blood loss occurs in AIDS and contributes
to the high incidence of anemia in this population. It is
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important to note that the anemia of HIV disease is
often multifactorial, and therefore much less blood
loss may precipitate symptoms. Early in chronic blood
loss, the red blood cell morphology is normal. As
chronic blood loss continues, the red blood cells
become hypochromic and microcytic, indicating an
inability of the bone marrow to adequately replace the
erythrocytes that are being lost through chronic bleed-
ing. The origin of chronic bleeding is most commonly
in the gastrointestinal tract. Abnormal uterine bleed-
ing due to reproductive tract malignancies is another
possibility in female patients. Hemorrhagic cystitis
due to infection may also be the etiology of chronic
bleeding (Ghez, Oksenhendler, Scieux, & Lassoued,
2000). Within the gastrointestinal tract, cytomega-
lovirus (CMV) is the most common cause, although
blood loss from gastrointestinal lymphoma or
Kaposi’s sarcoma may also contribute.
When blood loss occurs very slowly, patients adapt
and are often asymptomatic until the hemoglobin and
hematocrit become very low. The patient with AIDS
may be weakened by a number of other pathophysio-
logical processes, however, and may become symp-
tomatic earlier than a well person who develops
chronic blood loss. Chronic blood loss causes pallor,
fatigue, shortness of breath, light-headedness, dizzi-
ness, weakness, palpitations, and tinnitus. The pulse
pressure (systolic blood pressure minus the diastolic
blood pressure) widens due to peripheral vasodilation,
and a systolic ejection murmur may be noticeable.
These are physiological adaptations ensuring that tis-
sue oxygenation is maintained for as long as possible.
The oxyhemoglobin dissociation curve shifts to allow
more oxygen to leave the hemoglobin molecule and
diffuse into the tissues.
Treatment
Treatment of chronic blood loss is directed at ascer-
taining the etiology and appropriately treating it to
achieve hemostasis, whenever possible. Transfusions
may be required to return the hemoglobin and
hematocrit to normal values. Increasing dietary iron
sources is usually recommended, although iron can
irritate the gastric mucosa and should be used carefully
in the patient with AIDS-related gastrointestinal
diseases.
Acute Blood Loss Anemia
Pathophysiology
The individual with HIV disease is at risk for both
acute and chronic blood loss mainly through gastroin-
testinal bleeding, with upper gastrointestinal bleeding
occurring more commonly than lower. Because of
underlying thrombocytopenia, the risk of bleeding
from any lesions increases dramatically in the person
with AIDS (Chalasani & Wilcox, 1999). Upper gastro-
intestinal bleeding is most often associated with
non-HIV-related factors, such as peptic ulcer disease
and gastritis, whereas lower gastrointestinal bleeding
is more commonly associated with HIV. A number of
opportunistic infections can cause erosions and ulcer-
ations of the gastrointestinal mucosa. The most preva-
lent infection is with CMV, which is the most common
viral pathogen in patients with AIDS. CMV infection
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Table 7. Stages of Acute Blood Loss
Stage I Stage II Stage III Stage IV
Clinical Sign Initial Compensatory Progressive Final
Blood loss < 750 mL 750-1500 mL 1500-2000 mL > 2000 mL
Percentage blood volume < 15% 15%-30% 30%-40% > 40%
Heart rate Mildly elevated Moderately elevated Severely elevated Very severely elevated
Blood pressure Normal Normal Moderately decreased Severely decreased
Respirations Mildly elevated Moderately elevated Severely elevated Very severely elevated
Urine output Normal Mildly decreased Moderately decreased Severely decreased
Skin Cool, pink Cold, pale Cold, pale, moist Cold, mottled, moist
Thirst Mildly elevated Moderately elevated Severely elevated Very severely elevated
Table 8. Major Types of Anemia in HIV Disease
Mean Red
Mean Mean Corpuscular Blood Cell
Corpuscular Corpuscular Hemoglobin Distribution Other
Etiology Type Hemoglobin Hematocrit Volume Hemoglobin Concentration Reticulocytes Width Findings
Impaired production Anemia of chronic illness ↓ ↓ →↓ →↓ →↓ → →↑ Serum iron ↓
of erythrocytes Serum transferrin ↓
Serum ferritin ↓
Total iron-binding capacity ↓
Aplastic anemia ↓ ↓ →↑ → → ↓ →↑ Pancytopenia
Platelets < 20,000 cells/mm3
Retics < 40,000 cells/mm3
Iron deficiency anemia ↓ ↓ ↓ ↓ ↓ →↑↓ ↑ Serum iron ↓
Serum ferritin ↓
Transferrin saturation ↓




Serum vitamin B12 level ↓
Red blood cell vitamin B12 level ↓
Schilling’s test abnormal (< 2%)





Red blood cell folate ↓
Increased destruction Hereditary spherocytosis ↓ ↓ →↑ → → ↑ ↑ Indirect bilirubin ↑
of erythrocytes Lactic dehydrogenase ↑
Spherocytes present
Osmotic fragility test positive
Coombs’ test negative
Glucose-6-phosphate ↓ ↓ →↑ → → ↑ ↑ Hemoglobinemia
dehydrogenase deficiency Hemoglobinuria
anemia Indirect bilirubin ↑
Heinz bodies present





Increased loss Chronic blood loss ↓ ↓ →↑ → → ↑ → See text
of erythrocytes Acute blood loss ↓ ↓ →↑ → → ↑ → See text and Table 7
NOTE: ↓ = decrease, ↑ = increase, → = no change.
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of the gastrointestinal tract causes inflammatory
changes that lead to focal thrombosis, occlusion,
ischemia, and mucosal ulceration (Poles & Dieterich,
1996). The friable, damaged mucosa bleeds easily, and
ulcerative lesions may even perforate through the
muscularis mucosa. There are several sites of CMV
infection, but the esophagus and colon are the most
common. Esophageal involvement can occasionally
present as upper gastrointestinal bleeding, whereas
CMV colitis leads to hematochezia, diarrhea, cramp-
ing, and abdominal pain. Other causes of colitis in
AIDS include Cryptosporidium, Shigella, Salmonella,
Campylobacter, and Clostridium difficile. Anorectal
ulcerations and fissures are an additional, fairly com-
mon cause of bleeding in patients with AIDS and can
be due to CMV, Chlamydia, Treponema, herpes sim-
plex virus, and HIV (Poles & Dieterich, 1996).
Human immunodeficiency virus infection may be
associated with bacterial and fungal lesions in other
organs, which may ultimately lead to bleeding.
Subarachnoid hemorrhage due to cerebral
arteriopathy has been reported in AIDS (Mazzoni,
Chiriboga, Millar, & Rogers, 2000). Massive bleeding
into the peritoneum can also occur.
Acute blood loss occurs during hemorrhage, usu-
ally from the gastrointestinal tract or the uterus. In
hemophiliacs, bleeding may result from external or
internal injury. Hemorrhage into body cavities and
joint spaces should be considered. An acute event may
also be superimposed on a situation of chronic blood
loss. The volume of blood loss over time determines
the symptoms, which are related to hypovolemia with
consequent sympathetic nervous system activation.
Depending on the amount of blood loss and the
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Figure 2. Differential Diagnosis of HIV-Related Anemia (TIBC = total iron-binding capacity)
physical condition of the patient, hemorrhage may be
fatal if shock develops. Signs and symptoms of hemor-
rhagic shock include tachycardia, tachypnea, pallor,
cold, clammy skin, decreased urine formation, dry
mucous membranes, and weight loss. The anemia that
develops following acute blood loss is normocytic (see
Table 7).
Treatment
The debilitated patient with AIDS who suffers
hemorrhagic blood loss will require heroic lifesaving
efforts and transfusions to recover volume and oxygen-
carrying capacity in most cases. The volume of blood,
and the loss of cells, will be replaced over time if the
patient recovers from the massive bleeding, although it
may take 3 to 6 weeks for full recovery.
Differentiation of Anemia
The differentiation of anemia begins with a com-
plete history and physical examination. A complete
blood cell count is the next step in the differentiation.
Red blood cell size, determined by the mean corpuscu-
lar volume, helps to broadly classify anemia for differ-
ential diagnosis. Following the complete blood cell
count, a peripheral blood smear may provide useful
information. Common findings for each type of ane-
mia are presented in Table 8. Figure 2 provides a flow
chart to help with decision making.
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Questions
Select the best answer for the following questions:
1. The most common type of anemia in HIV disease
is
A. Iron deficiency anemia
B. Anemia of chronic illness
C. Folic acid deficiency anemia
D. Vitamin B12 deficiency anemia
E. Glucose-6-phosphate dehydrogenase defi-
ciency hemolytic anemia
2. A laboratory test that indicates the percentage of
blood cells in a given volume of whole blood is the
A. Hemoglobin
B. Hematocrit
C. Mean corpuscular hemoglobin concentration
D. Mean corpuscular volume
3. A mean corpuscular volume that is lower than nor-
mal indicates that the red blood cells are
A. Microcytic (too small)
B. Macrocytic (too large)
C. Normocytic (normal in size)
D. None of the above
4. Schilling’s test is useful in the differential diagno-
sis of vitamin B12 deficiency. If an individual
excretes ________ of the oral dose of radioac-
tively labeled vitamin B12, vitamin B12 deficiency
is not likely.
A. Greater than 7%
B. Less than 3%
C. Less than 5%
D. Less than 7%
5. Trimethoprim, methotrexate, and trimetrexate
antagonize the utilization of ________, whereas






6. Mary is a 30-year-old African American woman
who is HIV-positive but asymptomatic. Her CD4+
cell count is greater than 500, and her HIV-RNA
viral load is less than 50 copies/mm3. Her chief
complaint is “feeling tired all the time and exces-
sive menstrual bleeding.” Her hematological
parameters indicate that she has iron deficiency
anemia. Which of the following laboratory values
would you not expect?
A. Decreased mean corpuscular volume
B. Decreased mean corpuscular hemoglobin and
mean corpuscular hemoglobin concentration
C. Decreased total iron binding capacity
D. Increased serum ferritin
7. Intramuscular administration of iron dextran is
associated with increased risk of anaphylaxis.
A. True
B. False
8. The initial dose of epoietin alfa is 100 to 300
units/kg subcutaneously or intravenously three
times per week. The maintenance dose is titrated
to keep the hematocrit between
A. 12% and 16%
B. 36% and 40%
C. 42% and 46%
D. None of the above
9. There is strong evidence that ____________ defi-
ciency leads to neural tube deficits in the develop-
ing fetus.
A. Folic acid deficiency
B. Iron deficiency
C. Vitamin B12 deficiency
D. All the above
10. Vegetables such as asparagus, black eye peas, let-
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13. A low red blood cell count, hemoglobin, a normal
mean corpuscular volume, mean corpuscular
hemoglobin, and mean corpuscular hemoglobin in
association with a decreased total iron-binding
capacity, transferrin saturation, and an increased
serum ferritin suggests
A. Anemia of chronic illness
B. Iron deficiency anemia
C. Folic acid deficiency anemia
D. Hereditary spherocytosis
14. An elevated indirect bilirubin indicates
A. Hepatocellular damage
B. Iron deficiency anemia
C. Hemolytic anemia
D. All of the above
E. None of the above
15. Which of the following antiretrovirals is most




D. None of the above
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4. Do you understand the differences in treatment depending on the type
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5. Can you describe the various signs and symptoms of anemia?  
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